Jason Helfstein, Oppenheimer head of internet research, joins 'The Exchange' to discuss Spotify as the stock sinks on Q2 ...

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug ...

Fintel reports that on July 29, 2025, Oppenheimer initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Outperform recommendation. Analyst Price Forecast Suggests 201.20% Upside As of ...

The strategist — an industry veteran of 40 years who joined Goldman Sachs in 2002 — spoke to Bloomberg News about the outlook ...

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

Carvana Co. (NYSE:CVNA) is one of the best multibagger stocks according to hedge funds. On July 25, 2025, Oppenheimer analyst ...

This isn’t a generic re-run. These screenings are a testament to Nolan’s continued support for the IMAX format and enable ...

Jensen Huang believes questions of whether artificial intelligence (AI) could destroy humanity are fear-mongering — and get ...

The S&P 500 could match its best set of annual gains in three decades this year, analysts at Oppenheimer Asset Management say, as the tailwind from trade deals and improved corporate earnings carries ...

Progress in trade negotiations will take the S&P 500 to a third consecutive year of 20% gains, according to Oppenheimer Asset Management, a feat unseen since the late 1990s. Chief investment ...